Proceedings of the National Academy of Sciences
PNAS is the US National Academy of Sciences' multidisciplinary journal, home to many foundational cancer biology and cancer-modelling papers.
PNAS appears weekly and publishes across all sciences; cancer landmarks include early oncogene, tumour-suppressor and cancer-evolution modelling papers, mutational-signature methods and statistical work on cancer risk and screening. Hybrid access with free access after six months.
Tumours hide from T cells by displaying PD-L1; blocking that interaction lets the immune system attack. This is the mechanism of pembrolizumab, nivolumab, atezolizumab and their relatives, which now treat more than 20 cancer types.
Instead of blocking a cancer protein, a drug can now remove it entirely, which works even for proteins without a druggable active site and can overcome resistance driven by target overexpression or mutation. Several degraders are in late-stage trials for breast and prostate cancer.
Co-developed the HPV vaccine technology that is eliminating cervical cancer in vaccinated populations.
Isolated the first blood stem cells and discovered the 'don't eat me' signal CD47 on cancer cells.
Max Wicha identified breast cancer stem cells and made them a therapeutic target.
Nothing links here yet.